Dr Guido Di Napoli founded TRB Chemedica in 1980, laying the foundations for a company that has since expanded through a global network of subsidiaries and distributors.

In the early 1980s, TRB began building its presence in Asia, establishing offices in Hong Kong (1981), Singapore (1987), Malaysia (1988), and Thailand (1992). More recently, our network expanded to Vietnam.

Our journey in South America began in Brazil (1989) and extended to Argentina (1992), and later expanded to Mexico (2001). Today, Brazil and Argentina host two of our production plants, which are fully compliant with international GMP standards. They manufacture a broad range of products for musculoskeletal disorders, pain management, infectious diseases, and neurology. We are now present in more than nine countries across Latin America.

Established in Germany in 1996, TRB Chemedica AG, our German subsidiary, serves as our Centre of Competence. As a certified ISO 13485 site, it secures production and marketing authorisations for medical devices and manages the Quality Control and Safety Centre. Building on this strong foundation, TRB subsequently expanded its European presence with the opening of TRB Austria (2002) and TRB Poland (2006).

Since 1998, we’ve been leading the way in using sodium hyaluronate – the salt form of a natural molecule called hyaluronic acid, which helps keep body tissues hydrated and structurally healthy.¹ By working with high-quality sodium hyaluronate obtained through fermentation, TRB helped make this important treatment approach more widely available. This marked a significant step forward in the development of hyaluronic acid injections for joint care.

Importantly, the launch of OSTENIL® in 1998 set a new standard in osteoarthritis care as the first hyaluronic acid injection made through a fermentation process and approved for use in all synovial joints.

TRB UK and TRB France were founded in 2002, strengthening our distribution capacity across Europe. TRB UK is ISO 9001 certified, underscoring our commitment to quality and customer focus.

We were honoured that three of our products – OSTENIL®, OSTENIL® Plus, and OSTENIL® Mini – were listed on the official formulary for the London 2012 Olympic Games. They were the only hyaluronic-acid intra-articular injections included in the Pharmacy Guide for the Games.²

The first lubricant eye drops containing omega-3 fatty acids, designed to treat dry eye disease.

In 2019, we opened a representative office in Dubai to support our activities across the Middle East and Africa.

Alessandro Di Napoli was appointed CEO in 2019, continuing the family vision and leading the next phase of growth and innovation.

In 2024, TRB Italy was established, reinforcing our Southern European presence and commitment to patients and healthcare professionals in the region.